Sorrento goes to China with Covid drug; Vistagen touts early efficacy data on PMDD nasal spray
Sorrento Therapeutics’ oral Mpro inhibitor olgotrelvir has hit the primary endpoint and a key secondary endpoint in a Phase III trial that recruited adults with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
